MATTHEW MACLEAN: Open Payments
NPI 1972224491 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$584 in 29 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $32 · 2025 $584
Food & beverage: $584
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $144 |
| Novo Nordisk Inc | 5 | $110 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $82 |
| Dexcom, Inc. | 5 | $81 |
| ABBVIE INC. | 2 | $34 |
| Ardelyx, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| PFIZER INC. | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
Products named: XIFAXAN, Dexcom G6 Transmitter, Rybelsus, FARXIGA, AIRSUPRA, Wegovy, BREZTRI, WAINUA.
Industry payments across VA — which companies pay providers there.
